Back

Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: The heart and the kidney Renal Failure and Cardiovascular Disease ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
People with CKD in cardiovascular trials: a neglected population? A systematic review and evidence map
Ms J. Colombijn (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Impact of early stages of CKD with and without proteinuria on cardiac remodelling in UK Biobank cohort
Doctor H. Naderi (London, GB)
Abstract Slides Video
Presentation thumbnail
Renal insufficiency increases the risk of left ventricular remodeling
Doctor J. Liu (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Biomarker-based clinical subphenotypes of cardiac surgery associated acute kidney injury and their association with in-hospital treatments and outcomes: a data-driven cluster analysis
Doctor X. Huang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation on chronic haemodialysis: a systematic review and meta-analysis of randomised controlled trials
Ms M. Rodrigues Coutinho Clemente (Petropolis, BR)
Abstract Slides Video

Access the full session

Session thumbnail
The heart and the kidney
Video

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources